Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - eletriptan hydrobromide, quantity: 96.97 mg (equivalent: eletriptan, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; sunset yellow fcf; triacetin - acute treatment of migraine headache with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - eletriptan hydrobromide, quantity: 48.485 mg (equivalent: eletriptan, qty 40 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf; triacetin - acute treatment of migraine headache with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - eletriptan hydrobromide, quantity: 48.485 mg (equivalent: eletriptan, qty 40 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; sunset yellow fcf; triacetin - for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

Singapore - English - HSA (Health Sciences Authority)

viatris private limited - eletriptan hydrobromide eqv eletriptan - tablet, film coated - 40 mg - eletriptan hydrobromide eqv eletriptan 40 mg

Singapore - English - HSA (Health Sciences Authority)

pfizer pfe private limited - eletriptan hydrobromide eqv eletriptan - tablet, film coated - 80 mg - eletriptan hydrobromide eqv eletriptan 80 mg

United States - English - NLM (National Library of Medicine)

u.s. pharmaceuticals - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan 40 mg - relpax is indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with relpax, reconsider the diagnosis of migraine before relpax is administered to treat any subsequent attacks. - relpax is not intended for the prevention of migraine attacks. - safety and effectiveness of relpax have not been established for cluster headache. relpax is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1)]. - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)]. - history of stroke, transient ischemic attack (tia), or history or current evidence of hemipl

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - eletriptan - film-coated tablet - 40 milligram(s) - selective serotonin (5ht1) agonists; eletriptan

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - eletriptan - film-coated tablet - 20 milligram(s) - selective serotonin (5ht1) agonists; eletriptan

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - eletriptan hydrobromide - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - eletriptan hydrobromide - oral tablet - 40mg